MICROBIO GROUP
www.microbiogp.com

2022 Investor Conference

Corporate Presentation

2022.12.29

MICROBIO GROUP

Disclaimer

- The forward-looking statements mentioned in the presentation may include operating forecasts, financial status and marketing forecasts, based on information obtained from internal and external resources.
- There are numerous factors could cause actual results to be different from the implicit and explicit forecasts. The factors include, but are not limited to market risks, supply chain, market demand and our capability of launching high-quality products and services.
- Further, certain forward-looking statements are based on the company' s forecast of future events as of the date of this presentation. Oneness Biotech does not undertake any obligation to update or revise the forward-looking statements.

MICROBIO GROUP

Financial Report

As of 2022.12.29

2022 / 2021 Q3 Operation Status

2022 & 2021 Q3 Financial Reports

Item	2021Q3	2020Q3	Difference
Revenue	1,271,959	1,339,041	(67,082)
Operating loss	(212,367)	(597,305)	384,938
Net profit (loss)	660,526	(499,356)	1,159,882
Total Assets	15,762,130	13,593,534	2,168,596
Total Liabilities	1,063,974	1,039,937	24,037
Total Equity	14,698,156	12,553,597	2,144,559

Unit: NT$ thousand

2021-2022 Stock price chart



Closing Price	Day's Range	Year's Range	Market Value
62.4	61.5-65.3	51.2~79.3	31.9bn.

Unit: NT$

Consolidated Statements of Comprehensive Income

MICROBIO GROUP

Unit: NT$ thousand except EPS

Item	For the Nine Months Ended September 30		For the Three Months Ended September 30	
	2022	2021	2022	2021
Operating revenue	1,271,959	1,339,041	386,663	459,290
Operating costs	758,127	801,906	235,276	272,120
Operating gross profit	513,832	537,135	151,387	187,170
Selling expenses	401,973	394,623	138,936	134,641
Administrative expenses	134,893	238,265	47,687	39,693
R&D expenses	189,989	502,460	79,618	92,314
Total operating expenses	726,855	1,135,348	266,241	266,648
Other operating income and expenses	656	908	263	181
Loss from operations	(212,367)	(597,305)	(114,591)	(79,297)
Non-operating income	870,576	96,592	561,425	38,036
Income tax (profit) expense	(2,317)	(1,357)	461	-
Net profit (loss)	660,526	(499,356)	446,373	(41,261)
Earnings (Loss) per share (NT$)	1.31元	(0.66)元	0.83元	0.04元

Consolidated Balance Sheet

MICROBIO GROUP

Unit: NT$ thousand

Item	2022/9/30	2021/9/30	2021/12/31
Cash /Cash equivalents / Financial assets-current	4,147,400	4,099,706	4,061,173
Other current assets	390,407	358,019	424,434
Financial assets-noncurrent/ Investments accounted for using equity method	8,926,965	6,798,730	8,186,323
Property, plant and equipment	1,243,136	1,248,938	1,261,476
Right-of-use Asset	568,744	541,176	589,559
Intangible assets	211,609	275,470	222,000
Other assets	273,869	271,495	271,639
Total assets	15,762,130	13,593,534	15,016,604
Total liabilities	1,063,974	1,039,937	1,173,049
Share capital	5,110,972	4,663,296	4,663,296
Capital surplus	5,736,988	5,738,513	6,180,412
Retained earnings (Accumulated deficit)	702,673	(329,504)	49,981
Other equity	1,158,339	435,680	1,000,193
Non Controlling Interests	1,989,184	2,045,612	1,949,673
Total equity	14,698,156	12,553,597	13,843,555

Summary of Consolidated Financial Statements of the years Ended September 30,2022

MICROBIO GROUP

- **As of the third quarter of 2022, the consolidated net income after tax is 660,526 thousand NTD, and the main changes are explained as follows ：**

(1) Net Revenue ： 1,271,959 thousand NTD；Gross Profit： 513,832 thousand NTD

Operating income mainly comes from sales of medicines, health supplements, and revenue from Cotton Field Organic. A slight decrease of 67,082 thousand NTD compared with 2021Q3 was because the impact of the third-level alert of the epidemic last year. Consumers reduced dining out and increased the demand of organic products.

(2) Operating expenses：726,855 thousand NTD

The main expenses are 401,973 thousand NTD for sales and marketing expenses from medicines, health supplements and Cotton Field Organic, and 189,989 thousand NTD for research and development. The operating expenses of this period decreased by 408,493 thousand NTD compared with 2021Q3 was mainly because the BOD passed the resolution of transferring the treasury stocks to employees in the second quarter of last year, and the cost of employee compensation was recognized according to international accounting standards, but there was no such situation in this period.

(3) Net non-operating income：870,576 thousand NTD

It is mainly the investment gain recognized by using equity method for 685,966 thousand NTD which from the investee company recognized the unrealized evaluation gain from its investment targets and from the contract fee income that Oneness mainly recognized; also, this period recognized net foreign currency exchange benefits of 148,394 thousand NTD.

Summary of Consolidated Financial Statements of the years Ended September 30,2022

MICROBIO GROUP

■ Financial situation stable , important financial ratio :

Current ratio	Quick ratio	Debts ratio
1,103.40%	1,040.33%	6.75%

■ Important assets explanation :

Unit: NT $ thousand

Item	2022.9.30	2021.9.30	Explanations
Financial assets-noncurrent/ Investments accounted for using equity method	8,926,965	6,798,730	It is mainly Microbio recognized share of profit and other comprehensive income of associates accounted for using the equity method for 1,999,072 thousand NTD, and invested the Singapore company --Microbio Singapore Pte. Ltd. for 60,540 thousand NTD.
Retained earnings (Accumulated deficit)	702,673	(329,504)	Mainly the 2021 earnings appropriation of legal reserve 4,998 thousand NTD and special reserve 25,829 thousand NTD and the net profit after tax of 671,345 thousand NTD in the current period.
Other equity	1,158,339	435,680	The recognition of unrealized gain in value of financial assets measured at fair value through other comprehensive gains and losses (listed stocks) based on market price evaluation was 570,272 thousand NTD and the disposal of treasury stocks was 103,571 thousand NTD.

MICROBIO GROUP

Core value

MICROBIO GROUP

Microbio New Drug R&D

As of 2022.12.29

MICROBIO GROUP

Symbiota

Microbio New drug, MS-20

MS-20

The first new drug alleviating cancer therapy-related side effects in Taiwan (2011)



Drug license : 015926



The Sales of MS-20 in recent years

Unit: NT $ thousands



The Enormous Market Value for Cancer Immunotherapy

MICROBIO GROUP

- The global cancer immunotherapy market was valued at USD 85 billion in 2021 and expected to surpass around USD 277.1 billion by 2030, poised to grow at a compound annual growth rate (CAGR) of 12.6% from 2021 to 2030.
- The sales of cancer immunotherapy drug Keytruda increase yearly and generate more than $17 billion of revenue in 2021, which makes it the best selling drug globally.

https://www.precedenceresearch.com/cancer-immunotherapy-market https://www.axios.com/2021/10/29/keytruda-sales-merck-drug-prices

Microbiome affects the efficacy of Immunotherapy

MICROBIO GROUP

Science

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

V. Gopalakrishnan[1,2,*], C. N. Spencer[2,3,*], L. Nezi[2,*], A. Reuben[1], M. C. Andrews[1], T. V. Karpinets[1], P. A. Prieto[1,†], D. Vicente[1]...

+ See all authors and affiliations

Science 05 Jan 2018:
Vol. 359, Issue 6371, pp. 97-103
DOI: 10.1126/science.aan4236

2018 Jan. 《*Science*》

The compositions of gut microbiome determines the responsive rates of immune checkpoint drug.

Cell — Leading Edge — Perspective

Microbiome and Anticancer Immunosurveillance

Laurence Zitvogel,[1,2,3,*] Maha Ayyoub,[1,2,3] Bertrand Routy,[1,2,3] and Guido Kroemer[4,5,6,7,8,9,10,*]
[1]INSERM, U1015, Equipe labellisée Ligue Nationale Contre le Cancer, Gustave Roussy Cancer Campus, 95800 Villejuif, France
[2]University of Paris Sud XI, 94270 Le Kremlin-Bicêtre, France
*Correspondence: laurence.zitvogel@gustaveroussy.fr (L.Z.), kroemer@orange.fr (G.K.)
http://dx.doi.org/10.1016/j.cell.2016.03.001

2017 Jan. 《*Cell*》

Gut microbiome affects the recognition of cancer by immune system.



ARTICLE https://doi.org/10.1038/s41586-019-0878-z

A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

Takeshi Tanoue[1,2,3,16], Satoru Morita[1,10], Damian R. Plichta[4], Ashwin N. Skelly[1], Wataru Suda[3,5,6], Yuki Sugiura[7], Seiko Narushima[1,2], Hera Vlamakis[4], Ivri Motoo[7], Kayoko Sagitani[7], Atsushi Shiota[7,8], Kotaro Takeshita[7], Keiko Yasuma-Mitobe[7], Dieter Kleithmacher[9], Tsuneyasu Kaisho[7], Jason M. Norman[11], Daniel Macklin[11], Makoto Suematsu[7], Tomonori Yaguchi[12], Vanni Bucci[13], Takashi Inoue[14], Yutaka Kawakami[12], Bernat Olle[10], Bruce Roberts[10], Masahiro Hattori[2,3,5,6], Ramnik J. Xavier[4,15], Koji Atarashi[2,3] & Kenya Honda[1,2,3,4]

2019 Jan. 《*Nature*》

The compositions of microbiome regulates the number and activity of CD8 T cells, and thus affect the anti-tumor activity.

ORIGINAL ARTICLE

Gut microbiota modulate T cell trafficking into human colorectal cancer

Eleonora Cremonesi,[1] Valeria Governa,[2] Jesus Francisco Glaus Garzon,[3] Valentina Mele,[1] Francesca Amicarella,[1] Manuele Giuseppe Muraro,[2] Emanuele Trella,[2] Virginie Galati-Fournier,[4] Daniel Oertli,[5] Silvio Raffael Däster,[5] Raoul A Droeser,[5] Benjamin Weixler,[5] Martin Bolli,[6] Raffaele Rosso,[7] Ulrich Nitsche,[8] Nina Khanna,[9] Adrian Egli,[10] Simone Keck,[4] Julia Slotta-Huspenina,[11] Luigi M Terracciano,[12] Paul Zajac,[2] Giulio Cesare Spagnoli,[2] Serenella Eppenberger-Castori,[12] Klaus-Peter Janssen,[8] Lubor Borsig,[3] Giandomenica Iezzi[1]

2018 Nov. 《*Gut*》

Gut bacteria modulate cytokine to affect T cell trafficking and promote infiltration of immune cells into cancer.

Akkermansia Is A Key Factor to The Effectiveness of Anti-PD-1 Immunotherapy

MICROBIO GROUP

Science

572

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy[1,2,3], Emmanuelle Le Chatelier[4], Lisa Derosa[1,2,3], Connie P. M. Duong[1,2,5], Maryam Tidjani Alou[1,2,3], Romain D...

+ See all authors and affiliations

Science 05 Jan 2018:
Vol. 359, Issue 6371, pp. 91-97
DOI: 10.1126/science.aan3706

SHORT REPORT **Open Access**

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

Check for updates

Yi Zheng[1†], Tingting Wang[2†], Xiaoxuan Tu[1], Yun Huang[2], Hangyu Zhang[1], Di Tan[2], Weiqin Jiang[1], Shunfeng Cai[2], Peng Zhao[1], Ruixue Song[2], Peilu Li[2], Nan Qin[2,3*] and Weijia Fang[1,4,5,6*]

Journal for ImmunoTherapy of Cancer (2019) 7:193

The Diversity of Gut Microbiota and *Bifidobacterium longum* Influence Responses to Anti-PD-1 Immunotherapy on Lung Cancer

MICROBIO GROUP

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC

Check for updates

Yueping Jin, MD, PhD,[a] Hui Dong, PhD,[b] Liliang Xia, PhD,[a,c] Yi Yang, MD,[a] Yongqiang Zhu, MS,[b] Yan Shen, BS,[b] Huajun Zheng, PhD,[b] Chengcheng Yao, MS,[c] Ying Wang, PhD,[b,c] Shun Lu, MD, PhD[a,*]

[a]*Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China*
[b]*Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China*
[c]*Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China*





The diversity of gut microbiome affects the prevalence of CD8 T cells



J Thorac Oncol. 2019 Aug;14(8):1378-1389

Confidential

MS-20 reshapes gut microbiota

MICROBIO GROUP

The compositions

Taxonomic profiling



Richness | **Diversity**

Chao Index | Diversity Index



Control MS-20 Control MS-20

Microbiota network analysis







Long-term consumption of MS-20 increases Akkermansia

1. ***Akkermansia muciniphila***
2. ***Bacteroides thetaiotaomicron***
3. ***Bacteroides caccae***
4. ***Blautia obeum***
5. ***Bifidobacterium pseudocatenulatum***

LDA Effect Size (LEfSe): 1,000 X difference

MS-20 Improves Immunotherapy

MICROBIO GROUP

CT-26 Syngeneic Tumor Mouse Models

Animal Survival Rate(%)

Prominently increased the survival rates



Colon cancer model in Balb/c mice, n=12

Tumor Tissue

MS-20 Clinical Studies

Indications	Purpose	Population	Site
Immunotherapy	MS20 and PD-1 Combination Therapy	NSCLC patients	TMUH / CGMH Linkou / CGMH Kaohsiung / Taipei VGH
Pancreatic Cancer	Evaluation of MS20 on the Improvement of Pancreas Cancer-Induced Cachexia	Pancreatic cancer patients	NTUH
Inflammatory Bowel Disease (IBD)	Evaluation of MS-20 on IBD	Ulcerative colitis patients	NTUH / MMH Taipei

MICROBIO GROUP

Exploring new indications for MS-20

- Exploratory clinical trials are undergoing
- Evaluating new delivery route (rectal administration)
- Strategically marketing as medical foods in US to reduce time-to-market and expand the market size of MS-20

MICROBIO GROUP

New generation of Microbio Symbiota

- Symbiota as Anaerobic commensal bacteria metabolites, containing no live bacteria
- First generation symbiota, MS-20 had been approval by TFDA
- Symbiota improve syndrome or treat disease by modulating specific bacteria (increase beneficial ones and/or inhibit pathogens)
- 1200 symbiota have been generated via our Symbiotic Fermentation Platform function to increase beneficial bacteria and/or inhibit pathogens ready for new drug development

MICROBIO GROUP

Niche of Symbiota

- Unique patented platform developed for 20 years
- Increase specific beneficial bacteria while inhibit specific pathogens to modulate the microenvironment in gut or other organs
- Symbiota contain no live bacteria, function in gut regardless of microbiota colonization, high safety profile and stability
- Symbiota alter gut environment to regulate immune system
- Combined/add-on therapy with current drugs to maximize effect and speed up the drug development
- Expanding administration routes, including skin, nasal, rectal, to increase applicability

MICROBIO GROUP

New generation of Symbiota Library

Developing new drugs for treating cancer, autoimmune diseases and diabetes



MICROBIO GROUP

MB107

A Novel AhR Agonist for Skin Microbiota

MICROBIO GROUP

AhR, novel drug target

- Tapinarof (Dermavant Science), an AhR agonist, is a steroid-free topical cream shows strong efficacy on plaque psoriasis in two Phase-III trials, which was approved by FDA in August, 2022.
- Dermavant initiated two Phase-III trials for atopic dermatitis to study the efficacy of Tapinarof in September, 2021.

MICROBIO GROUP

The Market Potential of MB107

- MB107 shows potential therapeutic effects on plaque psoriasis and atopic dermatitis.
- The global plaque psoriasis (PsO) market was valued at $14.2 billion in 2020 and the projected market will reach 27.5 billion with the CAGR of 6.8%.
- The global market for atopic dermatitis is $12.7 billion and the projected market will reach 27.6 billion

GlobalData

GlobalData, Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030. ; 2021

MB107 ex vivo study





HaCaT cells: Immortalized human keratinocyte line

MB107 Reduces Erythema and Scale

Psoriasis



Atopic Dermatitis



MB107 Psoriasis Clinical Trial

MICROBIO GROUP

PASI score



PGA score



After 12 weeks of MB107 treatment, the erythema and scaling are largely reduced. When compared to baseline PASI is decreased by 80% and PGA is down by 50%

MB107 Alleviates Atopic Dermatitis-1







After 12 weeks of MB107 treatment, the erythema is obviously improved. When compared to baseline EASI is decreased by 69% and IGA is down by 49%

N=6 complete the trial
N=8 (+P111, P113)

MB107 Alleviates Atopic Dermatitis-2



The inhibition of Staphylococcus aureus is positively correlated with the clinical efficacy

MICROBIO GROUP

MB107, a novel AhR agonist, for plaque psoriasis and atopic dermatitis

- MB107 has been proven for a superior potency than Tapinarof ex vivo and in animal studies.
- Exploratory clinical trials for both plaque psoriasis and atopic dermatitis show positive results.
- Will strategically apply for medical devices due to the product features to shorten the time to the market.

MICROBIO GROUP

TCB

A Novel Multi
-target Nasal Symbiota therapy

MICROBIO GROUP

Multi-target Nasal Spray of Microbiome

- Modulates microbiota and maintains the homeostasis of normal microbiome
- Regulates immunity and maintains healthy host physiology
- Upholds the structural integrity of epithelial cells and adjusts mucus functions

MICROBIO GROUP

The Market Value for TCB

- TCB has the potential to treat chronic rhinosinusitis (CRS) and allergic rhinitis (AR).
- The global market for CRS is $2.13 billion USD in 2019, and is projected to rearch 3.5 billion USD by 2027 with a CAGR at 7.4%.
- The global market for AR is $13.5 billion USD in 2020, and is projected to rearch 3.5 billion USD by 2028 with a CAGR at 2.64%.

GlobalData, AR and CRS: Global Drug Forecast and Market Analysis to 2028. ; 2019

TCB Ex Vivo Study – Th2

Interleukin 5



Interleukin 13



TCB can suppress the releasing of key cytokines, IL-5 and IL-13, of Th2 immune cells

The ability of TCB to inhibit airway pathogens

MICROBIO GROUP

In vitro bacteriostasis test

Probiotics promoted by TCB	Pathogen inhibited by TCB	
Bifidobacterium Infantis (5%)	*Fusobacterium nucleatum*	*MIC= 2.5%*
Bifidobacterium latis Bb-12 (5%)	*Clostridium difficile*	*MIC= 1%*
Bifidobacterium longum (5%)	*Moraxella catarrhalis*	*MIC= 2%*
Akkermansia muciniphila (2.5%)	*Haemophilus influenza* (Airway-Anaerobes (Chronic sinusitis))	*MIC= 5%*
Bifidobacterium Bifidum (2%)	*Pseudomonas aeruginosa*	*MIC= 5%*
Bifidobacterium adolescentis	*Streptococcus pneumonia*	*MIC= 5%*
The ability of TCB to protect probiotics from antibiotics (Amoxicillin)	*Bacteroides fragilis* (Airway-Aerobes (Acute sinusitis))	*MIC= 5%*
	Propionibacterium acnes	*MIC= 5%*
	Escherichia coli (Allergic disease)	*MIC= 1%*
L. paracasei (5%)	*Klebsiella pneumonia*	*MIC= 1%*
L. bulgaricus (5%)	*Staphylococcus aureus*	*MIC ≦2.5%*
L. rhamnosus (5%)	*Oxacillin resistant staphylococcus aureus*	*MIC ≦1.56%*
(1) *L. paracasei* is a mucosa-associated species that reduces allergy through ↓ Th-2 cell, IL-4, and IgE; it can reduce the frequency and degree of allergic rhinitis (2004, Wang).	*Methicillin resistant staphylococcus aureus*	*MIC= 1%*
	Mycobacterium ranae	*MIC= 3%*
	Proteus vulgaris	*MIC= 1%*
(2) *L. rhamnosus:* Among them, L. rhamnosus GG is currently the most researched probiotic in the world. Human trials have found that it can reduce allergic reactions such as atopic dermatitis and eczema.	*Salmonella typhimurium*	*MIC ≦2.5%*
	Vancomycin-resistant enterococcus faecalis	*MIC ≦1.25%*
	Helicobacter pylori	*MIC ≦5%*

TCB Ex Vivo Study–Bioflim



TCB, a dual immune and microbiome modulator for CRS and AR

- Inhibits Th2 immune response equivalently to steroids ex vivo.
- Suppresses the growth of opportunistic pathogens ex vivo.
- Prevents the formation of biofilm in ex vivo studies.
- Downregulates bacterial infection-induced chronic inflammation.
- Exploratory clinical trials will be initiated in 2023
- Will strategically apply for medical devices due to the product features to shorten the time to the market.

MICROBIO GROUP

TB90010

Symbiota for Type 2 Diabetes

MICROBIO GROUP

TB90010-T2DM Symbiota

1. The efficacy for type 2 diabetes was shown in ex vivo and animal studies.
2. The exploratory trial of TB90010 and Metformin combination is completed.

TB90010/Metformin combination therapy

In patients refractory to Metformin, 75% of patients respond to the combination therapy with HbA1c reduction





9/12 stable or improved

75% patients

After treatment increased beneficial (green) and decreased adverse (red) bacterium

TB90010/Metformin combination therapy

In the subgroup analysis, the better responders (50%) reduce their HbA1c by 0.58%





TB90010/Metformin combination therapy

The gut bacteria biomarkers for responders and non-responders



B-V1: Better baseline, P-V1: Poor baseline

Enriched in better responder

- *Clostriales*
- *Bacteroidales*
- *Prevotella*
- *Lachnospiraceae*
- *Blautia*

Enriched in poor responder

- *Lactobacilliales*
- *Bacilli*
- *Gammaproteobacteria*
- *Erysipelotrichaceae*
- *Enterobacteriaceae*
- *Klebsiella pneumoniae*

MICROBIO GROUP

TB90010/Metformin combination therapy

For people regularly receiving Metformin whose HbA1c is still above 7.0% (Metformin treatment failure patients) :

- No changes in the parameters related to liver and kidney and no product-related adverse events indicate good safety and tolerance of Symbiota.
- Significant enrichment in butyrate-producing bacteria in microbiota analyis
- In the subgroup analysis, the better responders (50%) reduce their HbA1c by 0.58%
- Discovering biomarkers as predictive makers for stabilizing or reducing blood glucose levels in the subjects receiving TB90010 treatment

MICROBIO GROUP

FDA approval opens a new era of microbiome-based therapy

- 2022 Nov. USFDA approved the first microbiome-based therapy.
- This new drug of microbiome has a breakthrough in both science and regulation.
- PK and toxicological studies in human may be exempt.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product

Important Subsidiary – Microbio Shanghai – 1

- Year of Establishment: 2004
- Capital: NTD 1.9bn

  (Fund raised US$ 100M)
- Type of Entity: Co., Ltd.

  (Joint Investment from Hong Kong, Macao and Taiwan)
- Type of Business: R&D in medicine and biotech

Research Center

Songjiang plant

Important Subsidiary – Microbio Shanghai – 2

MICROBIO GROUP

Goal：Rising biotech start-up in mainland China

Strategy：

1. Accelerated market entry of new drug pipelines into China market
2. Connect with scientists across straits for collaboration on new drugs based on in-house technology platform
3. Enhance business and operation via M&A
4. Establish co-development with international pharmas via licensing collaboration
5. Enter into capital market for long-term operation

Important Subsidiary – Microbio Shanghai – 3

New Drug Pipeline

Code	Category	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	NDA	Milestones
MBS-DM	Microbiome	T2DM						
MBS-217	Microbiome	NAFLD						
MBS-COV	Nucleic acid	COVID-19						Phase2 Est. 2023 Q2
MBS-HIF1A	Nucleic acid	HCC						IND Est. 2024 Q1
MBS-HBV	Nucleic acid	HBV						

Code	Category	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	NDA	Milestones
MS-20	Microbiome	Immuno-oncology						MICROBIO
Herbiron	Botanical	Dysmenorrhea, Anemia						MICROBIO
ON101	Botanical	Diabetic foot ulcer						ONENESS
OB318	Small molecule	HCC						ONENESS
FB825	Antibody	Atopic Dermatitis						ONENESS
		Allergic Asthma						
FB704A	Antibody	Neutrophilic Asthma						ONENESS
FB918	Antibody	Allergic						ONENESS

Important Subsidiary – Cotton Field Organic-1

The main sales channel of organic products

- Year of Establishment: 1994
- Capital: NTD 0.5bn
- Type of Business : retail sales, e-commerce, electronic delivery platforms, organic farms
- Total 68 retail stores in Taiwan with highest coverage in Taipei and New Taipei

Important Subsidiary – Cotton Field Organic-2 Advantages

MICROBIO GROUP

自主開發 獨家品項

與中天生技合作，推廣健康、保健、營養類產品

嚴選 國際化商品

引進歐盟、FDA、有機認證優質產品

有機商品 業界最高標準

100% 有機佔比 → 生鮮蔬菜 根莖瓜果

80% 有機佔比 → 乾貨 冷凍品

設立檢驗室 抽驗層層把關

深化落實 ESG

關注永續理念與社會責任

Food Safety



Important Subsidiary – Cotton Field Organic-3 2019-2022 revenue

MICROBIO GROUP

Unit: NT $ thousands



MICROBIO GROUP

Investment

MICROBIO
中天生物科技股份有限公司

Cotton field	Microsoy International Inc.	Microbio (Shanghai)	Oneness (OTC)	Diamond Biofund (Emerging Stock Market)	Sun Biofund	Jing Ying Invest	Microbio Singapore Pte.Ltd.
72.7%	100%	58.4%	20.3%	28.8%	26.3%	28.9%	33.3%
Total Amount of Paid-in Capital $5.9bn	Total Amount of Paid-in Capital $0.5bn	Total Amount of Paid-in Capital $19bn	Total Amount of Paid-in Capital $38bn	Total Amount of Paid-in Capital $63bn	Total Amount of Paid-in Capital $35bn	Total Amount of Paid-in Capital $15bn	Total Amount of Paid-in Capital $1.8bn

Reinvestment Valuation

Book Value and (loss) Gain from Investment Accounted under the Equity Method

MICROBIO GROUP

(Currency in thousand TWD)

Company	Share holding ratio	Original Investment	2022.09.30 Book value	2022 Q1-Q3 Recognized Investment (loss) Gain
Oneness (4743)	20.28%	1,564,909	3,169,271	203,929
Diamond Biofund(6901)	28.76%	836,433	3,482,852	533,782
Jing Ying Invest	28.88%	450,739	472,492	(158)
Sun Biofund	26.32%	903,445	1,302,323	(11,029)
Microbio Singapore Pte. Ltd.	33.33%	60,540	63,357	1,561
Cotton field Organic Farm	49.00%	147,000	231,106	(42,119)
Total		3,963,066	8,721,401	685,966

Above statement excludes subsidaries: Cotton field , Microsoy and Microbio (Shanghai)

MICROBIO GROUP

Q & A

MICROBIO GROUP

Thank you!